BillionToOne, Inc. (NASDAQ: BLLN) Stock Competitors & Peer Comparison
See BLLN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BLLN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BLLN | $105.41 | +4.55% | 4.8B | 148.96 | $0.70 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.69% |
| TMO | $647.89 | +5.67% | 238.4B | 27.70 | $23.16 | +0.29% |
| DHR | $209.36 | +3.01% | 147.1B | 26.23 | $7.98 | +0.69% |
| NTRA | $349.44 | +2.24% | 50.2B | -265.74 | -$1.32 | N/A |
| IQV | $270.94 | +1.98% | 44.4B | 22.22 | $12.13 | N/A |
| A | $153.58 | +4.62% | 42.4B | 25.85 | $5.81 | +0.67% |
| IDXX | $519.83 | +2.02% | 40.3B | 35.92 | $14.22 | N/A |
| ILMN | $228.00 | +9.51% | 33.6B | 44.19 | $5.03 | N/A |
| WAT | $420.59 | +2.58% | 31.2B | 30.49 | $13.68 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
BLLN vs DHR-PB Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, BLLN's ROE is +0.08%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, BLLN is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
BLLN vs TMO Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, TMO has a market cap of 238.4B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while TMO trades at $647.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas TMO's P/E ratio is 27.70. In terms of profitability, BLLN's ROE is +0.08%, compared to TMO's ROE of +0.13%. Regarding short-term risk, BLLN is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
BLLN vs DHR Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, DHR has a market cap of 147.1B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while DHR trades at $209.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas DHR's P/E ratio is 26.23. In terms of profitability, BLLN's ROE is +0.08%, compared to DHR's ROE of +0.08%. Regarding short-term risk, BLLN is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
BLLN vs NTRA Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, NTRA has a market cap of 50.2B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while NTRA trades at $349.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas NTRA's P/E ratio is -265.74. In terms of profitability, BLLN's ROE is +0.08%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, BLLN is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check NTRA's competition here
IQVIA Holdings Inc. (NYSE: IQV)
BLLN vs IQV Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, IQV has a market cap of 44.4B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while IQV trades at $270.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas IQV's P/E ratio is 22.22. In terms of profitability, BLLN's ROE is +0.08%, compared to IQV's ROE of +0.22%. Regarding short-term risk, BLLN is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check IQV's competition here
Agilent Technologies, Inc. (NYSE: A)
BLLN vs A Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, A has a market cap of 42.4B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while A trades at $153.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas A's P/E ratio is 25.85. In terms of profitability, BLLN's ROE is +0.08%, compared to A's ROE of +0.20%. Regarding short-term risk, BLLN is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check A's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
BLLN vs IDXX Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, IDXX has a market cap of 40.3B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while IDXX trades at $519.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas IDXX's P/E ratio is 35.92. In terms of profitability, BLLN's ROE is +0.08%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, BLLN is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
BLLN vs ILMN Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, ILMN has a market cap of 33.6B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while ILMN trades at $228.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas ILMN's P/E ratio is 44.19. In terms of profitability, BLLN's ROE is +0.08%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, BLLN is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check ILMN's competition here
Waters Corporation (NYSE: WAT)
BLLN vs WAT Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, WAT has a market cap of 31.2B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while WAT trades at $420.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas WAT's P/E ratio is 30.49. In terms of profitability, BLLN's ROE is +0.08%, compared to WAT's ROE of +0.02%. Regarding short-term risk, BLLN is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check WAT's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
BLLN vs DGX Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, DGX has a market cap of 27.3B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while DGX trades at $246.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas DGX's P/E ratio is 24.39. In terms of profitability, BLLN's ROE is +0.08%, compared to DGX's ROE of +0.14%. Regarding short-term risk, BLLN is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check DGX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
BLLN vs MTD Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, MTD has a market cap of 26.9B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while MTD trades at $1,376.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas MTD's P/E ratio is 30.58. In terms of profitability, BLLN's ROE is +0.08%, compared to MTD's ROE of -12.00%. Regarding short-term risk, BLLN is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
BLLN vs LH Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, LH has a market cap of 25.9B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while LH trades at $324.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas LH's P/E ratio is 18.72. In terms of profitability, BLLN's ROE is +0.08%, compared to LH's ROE of +0.12%. Regarding short-term risk, BLLN is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
BLLN vs GH Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, GH has a market cap of 23.6B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while GH trades at $176.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas GH's P/E ratio is -50.33. In terms of profitability, BLLN's ROE is +0.08%, compared to GH's ROE of +2.11%. Regarding short-term risk, BLLN is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
BLLN vs EXAS Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas EXAS's P/E ratio is -95.37. In terms of profitability, BLLN's ROE is +0.08%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, BLLN is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
BLLN vs MEDP Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while MEDP trades at $618.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas MEDP's P/E ratio is 36.37. In terms of profitability, BLLN's ROE is +0.08%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, BLLN is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
BLLN vs ILMNV Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas ILMNV's P/E ratio is N/A. In terms of profitability, BLLN's ROE is +0.08%, compared to ILMNV's ROE of N/A. Regarding short-term risk, BLLN is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
BLLN vs RVTY Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, RVTY has a market cap of 15.6B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while RVTY trades at $145.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas RVTY's P/E ratio is 26.19. In terms of profitability, BLLN's ROE is +0.08%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, BLLN is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
BLLN vs PKI Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas PKI's P/E ratio is 41.45. In terms of profitability, BLLN's ROE is +0.08%, compared to PKI's ROE of +0.03%. Regarding short-term risk, BLLN is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
BLLN vs ICLR Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while ICLR trades at $174.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas ICLR's P/E ratio is 14.07. In terms of profitability, BLLN's ROE is +0.08%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, BLLN is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check ICLR's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
BLLN vs CRL Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, CRL has a market cap of 13.1B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while CRL trades at $279.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas CRL's P/E ratio is 27.53. In terms of profitability, BLLN's ROE is +0.08%, compared to CRL's ROE of -0.08%. Regarding short-term risk, BLLN is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check CRL's competition here
Qiagen N.V. (NYSE: QGEN)
BLLN vs QGEN Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, QGEN has a market cap of 8.8B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while QGEN trades at $43.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas QGEN's P/E ratio is 17.55. In terms of profitability, BLLN's ROE is +0.08%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, BLLN is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
BLLN vs RDNT Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, RDNT has a market cap of 6.1B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while RDNT trades at $77.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas RDNT's P/E ratio is 167.65. In terms of profitability, BLLN's ROE is +0.08%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, BLLN is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
BLLN vs SHC Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, SHC has a market cap of 5.4B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while SHC trades at $19.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas SHC's P/E ratio is 19.77. In terms of profitability, BLLN's ROE is +0.08%, compared to SHC's ROE of +0.27%. Regarding short-term risk, BLLN is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
BLLN vs SYNH Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas SYNH's P/E ratio is 61.40. In terms of profitability, BLLN's ROE is +0.08%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, BLLN is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check SYNH's competition here
GRAIL Inc. (NASDAQ: GRAL)
BLLN vs GRAL Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, GRAL has a market cap of 3.3B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while GRAL trades at $76.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas GRAL's P/E ratio is -7.78. In terms of profitability, BLLN's ROE is +0.08%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, BLLN is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check GRAL's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
BLLN vs OLK Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas OLK's P/E ratio is -96.59. In terms of profitability, BLLN's ROE is +0.08%, compared to OLK's ROE of -0.07%. Regarding short-term risk, BLLN is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check OLK's competition here
Veracyte, Inc. (NASDAQ: VCYT)
BLLN vs VCYT Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while VCYT trades at $40.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas VCYT's P/E ratio is 20.07. In terms of profitability, BLLN's ROE is +0.08%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, BLLN is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check VCYT's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
BLLN vs WGS Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, WGS has a market cap of 2.8B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while WGS trades at $98.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas WGS's P/E ratio is 262.89. In terms of profitability, BLLN's ROE is +0.08%, compared to WGS's ROE of -0.39%. Regarding short-term risk, BLLN is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check WGS's competition here
CareDx, Inc (NASDAQ: CDNA)
BLLN vs CDNA Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, CDNA has a market cap of 2.7B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while CDNA trades at $54.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas CDNA's P/E ratio is 62.67. In terms of profitability, BLLN's ROE is +0.08%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, BLLN is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
BLLN vs PSNL Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while PSNL trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas PSNL's P/E ratio is -14.77. In terms of profitability, BLLN's ROE is +0.08%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, BLLN is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
BLLN vs OPK Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while OPK trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas OPK's P/E ratio is -5.81. In terms of profitability, BLLN's ROE is +0.08%, compared to OPK's ROE of -0.06%. Regarding short-term risk, BLLN is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
BLLN vs CSTL Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while CSTL trades at $35.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas CSTL's P/E ratio is -53.79. In terms of profitability, BLLN's ROE is +0.08%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, BLLN is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
BLLN vs FLGT Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, FLGT has a market cap of 604.4M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while FLGT trades at $21.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas FLGT's P/E ratio is 2128.00. In terms of profitability, BLLN's ROE is +0.08%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, BLLN is similarly volatile compared to FLGT. This indicates similar risk in terms of short-term price fluctuations for BLLN.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
BLLN vs GRALV Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas GRALV's P/E ratio is N/A. In terms of profitability, BLLN's ROE is +0.08%, compared to GRALV's ROE of N/A. Regarding short-term risk, BLLN is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
BLLN vs NEO Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, NEO has a market cap of 485.4M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while NEO trades at $19.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas NEO's P/E ratio is 145.31. In terms of profitability, BLLN's ROE is +0.08%, compared to NEO's ROE of -0.06%. Regarding short-term risk, BLLN is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
BLLN vs CO Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas CO's P/E ratio is 5.06. In terms of profitability, BLLN's ROE is +0.08%, compared to CO's ROE of +0.11%. Regarding short-term risk, BLLN is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
BLLN vs MYGN Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, MYGN has a market cap of 366.5M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while MYGN trades at $4.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas MYGN's P/E ratio is -29.85. In terms of profitability, BLLN's ROE is +0.08%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, BLLN is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
BLLN vs FLDM Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas FLDM's P/E ratio is -4.74. In terms of profitability, BLLN's ROE is +0.08%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, BLLN is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check FLDM's competition here
Prenetics Global Limited (NASDAQ: PRENW)
BLLN vs PRENW Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, PRENW has a market cap of 277.8M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas PRENW's P/E ratio is N/A. In terms of profitability, BLLN's ROE is +0.08%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, BLLN is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check PRENW's competition here
Biodesix, Inc. (NASDAQ: BDSX)
BLLN vs BDSX Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, BDSX has a market cap of 225.5M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while BDSX trades at $28.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas BDSX's P/E ratio is -8.74. In terms of profitability, BLLN's ROE is +0.08%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, BLLN is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
BLLN vs XGN Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, XGN has a market cap of 181M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while XGN trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas XGN's P/E ratio is -9.25. In terms of profitability, BLLN's ROE is +0.08%, compared to XGN's ROE of -1.22%. Regarding short-term risk, BLLN is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
BLLN vs IMDX Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, IMDX has a market cap of 129.8M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while IMDX trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas IMDX's P/E ratio is -2.70. In terms of profitability, BLLN's ROE is +0.08%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, BLLN is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
BLLN vs GTH Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas GTH's P/E ratio is -1.11. In terms of profitability, BLLN's ROE is +0.08%, compared to GTH's ROE of -1.01%. Regarding short-term risk, BLLN is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
BLLN vs GENE Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas GENE's P/E ratio is -38.25. In terms of profitability, BLLN's ROE is +0.08%, compared to GENE's ROE of -1.85%. Regarding short-term risk, BLLN is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
BLLN vs SERA Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, SERA has a market cap of 76M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while SERA trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas SERA's P/E ratio is -3.06. In terms of profitability, BLLN's ROE is +0.08%, compared to SERA's ROE of -0.47%. Regarding short-term risk, BLLN is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
BLLN vs PRPO Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, PRPO has a market cap of 48.6M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while PRPO trades at $25.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas PRPO's P/E ratio is -104.77. In terms of profitability, BLLN's ROE is +0.08%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, BLLN is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
BLLN vs MDXH Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, MDXH has a market cap of 34.6M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while MDXH trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas MDXH's P/E ratio is -1.77. In terms of profitability, BLLN's ROE is +0.08%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, BLLN is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
BLLN vs QUCY Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, QUCY has a market cap of 30.5M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while QUCY trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas QUCY's P/E ratio is -0.06. In terms of profitability, BLLN's ROE is +0.08%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, BLLN is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
BLLN vs AKU Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas AKU's P/E ratio is -0.13. In terms of profitability, BLLN's ROE is +0.08%, compared to AKU's ROE of -5.32%. Regarding short-term risk, BLLN is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
BLLN vs CEMI Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas CEMI's P/E ratio is -0.63. In terms of profitability, BLLN's ROE is +0.08%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, BLLN is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
BLLN vs ENZ Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas ENZ's P/E ratio is -2.24. In terms of profitability, BLLN's ROE is +0.08%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, BLLN is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
BLLN vs PMD Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas PMD's P/E ratio is -5.24. In terms of profitability, BLLN's ROE is +0.08%, compared to PMD's ROE of -0.32%. Regarding short-term risk, BLLN is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
BLLN vs ME Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas ME's P/E ratio is -0.03. In terms of profitability, BLLN's ROE is +0.08%, compared to ME's ROE of -42.03%. Regarding short-term risk, BLLN is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
BLLN vs MYNZ Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, BLLN's ROE is +0.08%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, BLLN is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
BLLN vs BNR Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, BNR has a market cap of 12.2M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while BNR trades at $13.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas BNR's P/E ratio is -13.29. In terms of profitability, BLLN's ROE is +0.08%, compared to BNR's ROE of -0.13%. Regarding short-term risk, BLLN is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check BNR's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
BLLN vs ADVB Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, ADVB has a market cap of 11.2M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while ADVB trades at $8.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas ADVB's P/E ratio is -73.45. In terms of profitability, BLLN's ROE is +0.08%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, BLLN is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check ADVB's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
BLLN vs CHEK Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas CHEK's P/E ratio is -0.43. In terms of profitability, BLLN's ROE is +0.08%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, BLLN is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
BLLN vs CNTG Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas CNTG's P/E ratio is -0.23. In terms of profitability, BLLN's ROE is +0.08%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, BLLN is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check CNTG's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
BLLN vs NDRA Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, NDRA has a market cap of 7.3M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while NDRA trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas NDRA's P/E ratio is -0.73. In terms of profitability, BLLN's ROE is +0.08%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, BLLN is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
BLLN vs APDN Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas APDN's P/E ratio is -0.10. In terms of profitability, BLLN's ROE is +0.08%, compared to APDN's ROE of -7.23%. Regarding short-term risk, BLLN is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
BLLN vs NVTA Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas NVTA's P/E ratio is -0.00. In terms of profitability, BLLN's ROE is +0.08%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, BLLN is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
BLLN vs LMDXW Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, BLLN's ROE is +0.08%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, BLLN is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
BLLN vs LMDX Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas LMDX's P/E ratio is -0.01. In terms of profitability, BLLN's ROE is +0.08%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, BLLN is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check LMDX's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
BLLN vs BIAFW Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, BIAFW has a market cap of 4.6M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while BIAFW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas BIAFW's P/E ratio is 0.49. In terms of profitability, BLLN's ROE is +0.08%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, BLLN is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check BIAFW's competition here
DermTech, Inc. (NASDAQ: DMTK)
BLLN vs DMTK Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas DMTK's P/E ratio is -0.04. In terms of profitability, BLLN's ROE is +0.08%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, BLLN is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
BLLN vs NOTV Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas NOTV's P/E ratio is -0.03. In terms of profitability, BLLN's ROE is +0.08%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, BLLN is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check NOTV's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
BLLN vs BIAF Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, BIAF has a market cap of 2.6M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while BIAF trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas BIAF's P/E ratio is -0.73. In terms of profitability, BLLN's ROE is +0.08%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, BLLN is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
BLLN vs SQL Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas SQL's P/E ratio is -0.40. In terms of profitability, BLLN's ROE is +0.08%, compared to SQL's ROE of -30.46%. Regarding short-term risk, BLLN is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
BLLN vs AWH Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas AWH's P/E ratio is -0.09. In terms of profitability, BLLN's ROE is +0.08%, compared to AWH's ROE of +1.62%. Regarding short-term risk, BLLN is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
BLLN vs HTGM Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas HTGM's P/E ratio is -0.03. In terms of profitability, BLLN's ROE is +0.08%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, BLLN is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
BLLN vs BIOC Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas BIOC's P/E ratio is -0.01. In terms of profitability, BLLN's ROE is +0.08%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, BLLN is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
BLLN vs ISPC Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, ISPC has a market cap of 184.7K. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while ISPC trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas ISPC's P/E ratio is -0.04. In terms of profitability, BLLN's ROE is +0.08%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, BLLN is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
BLLN vs SQLLW Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, BLLN's ROE is +0.08%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, BLLN is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
BLLN vs WGSWW Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, BLLN's ROE is +0.08%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, BLLN is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check WGSWW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
BLLN vs MEUSW Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas MEUSW's P/E ratio is N/A. In terms of profitability, BLLN's ROE is +0.08%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, BLLN is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check MEUSW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
BLLN vs NDRAW Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas NDRAW's P/E ratio is N/A. In terms of profitability, BLLN's ROE is +0.08%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, BLLN is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check NDRAW's competition here
Danaher Corporation (NYSE: DHR-PA)
BLLN vs DHR-PA Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, BLLN's ROE is +0.08%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, BLLN is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check DHR-PA's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
BLLN vs PRXL Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas PRXL's P/E ratio is 42.97. In terms of profitability, BLLN's ROE is +0.08%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, BLLN is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check PRXL's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
BLLN vs OCDX Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas OCDX's P/E ratio is -42.28. In terms of profitability, BLLN's ROE is +0.08%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, BLLN is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for BLLN.Check OCDX's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
BLLN vs BNGOW Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas BNGOW's P/E ratio is N/A. In terms of profitability, BLLN's ROE is +0.08%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, BLLN is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
BLLN vs CHEKZ Comparison September 2026
BillionToOne, Inc. (NASDAQ: BLLN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLLN stands at 4.8B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, BLLN is priced at $105.41 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLLN currently has a P/E ratio of 148.96, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, BLLN's ROE is +0.08%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, BLLN is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for BLLN.Check CHEKZ's competition here